STRATA Skin Sciences Inc
NASDAQ:SSKN
Intrinsic Value
STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. [ Read More ]
The intrinsic value of one
SSKN
stock under the Base Case scenario is
1.13
USD.
Compared to the current market price of 0.54 USD,
STRATA Skin Sciences Inc
is
Undervalued by 52%.
STRATA Skin Sciences Inc's market capitalization is 18.9m USD.
SSKN stock price is 0.54 USD.
SSKN stock price (0.54 USD) is 52% less than its Intrinsic Value (1.13 USD).
SSKN. Open DCF Valuation
SSKN has upside potential of 476% compared to the average analyst price target.
Open Wall St Estimates
SSKN's ROIC (Return on Invested Capital) has increased in the last 3 years from -17% to -17%, and is approaching profitability.
SSKN's D/E (Debt to Equity) is equal to 1.19.
SSKN's Revenue has dropped by 8% over the past 12 months.
SSKN's short-term assets (16m USD) exceed its short-term liabilties (12m USD).
SSKN has positive Net Debt. This means that the company has more debt (15m USD) than cash and short-term investments (7m USD).
SSKN's long-term assets (42m USD) exceed its long-term liabilties (29m USD).
SSKN's Revenue has been growing by 13% per year for the last 3 years.
SSKN's ROE (Return on Equity) has significantly decreased in the last 3 years from -22% to -63%, and is approaching profitability.
SSKN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -17%.
SSKN has negative Operating Income for the last twelve months.
SSKN has negative Net Income for the last twelve months.
SSKN's ROE (Return on Equity) for the past 12 months is negative and is equal to -63%.
SSKN has positive Gross Profit for the last twelve months.
SSKN has negative Free Cash Flow for the last twelve months.
SSKN has negative three-year average ROIC (Return on Invested Capital): -14%. The company is not efficient at using invested capital to generate operating income.
SSKN has negative three-year average ROE (Return on Equity): -25%. The company is not efficient at transforming stockholders' equity into net income.
SSKN's Altman Z-Score is very low and is equal to -7.34.
SSKN doesn't generate enough operating income (-6m USD) to safely cover interest payments on its debt (1m USD).
Valuation Backtest
STRATA Skin Sciences Inc
Run backtest to discover the historical profit from buying and selling
SSKN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
STRATA Skin Sciences Inc
Balance Sheet Decomposition
STRATA Skin Sciences Inc
| Current Assets | 15.5m |
| Cash & Short-Term Investments | 6.8m |
| Receivables | 4.4m |
| Other Current Assets | 4.3m |
| Non-Current Assets | 26.5m |
| PP&E | 12.4m |
| Intangibles | 13.8m |
| Other Non-Current Assets | 231k |
| Current Liabilities | 12.2m |
| Accounts Payable | 3.3m |
| Accrued Liabilities | 6.7m |
| Other Current Liabilities | 2.2m |
| Non-Current Liabilities | 17.2m |
| Long-Term Debt | 15m |
| Other Non-Current Liabilities | 2.1m |
Earnings Waterfall
STRATA Skin Sciences Inc
|
Revenue
|
33.4m
USD
|
|
Cost of Revenue
|
-14.9m
USD
|
|
Gross Profit
|
18.5m
USD
|
|
Operating Expenses
|
-24.8m
USD
|
|
Operating Income
|
-6.3m
USD
|
|
Other Expenses
|
-4.5m
USD
|
|
Net Income
|
-10.8m
USD
|
Free Cash Flow Analysis
STRATA Skin Sciences Inc
What is Free Cash Flow?
SSKN Profitability Score
Profitability Due Diligence
STRATA Skin Sciences Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
STRATA Skin Sciences Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
SSKN Solvency Score
Solvency Due Diligence
STRATA Skin Sciences Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Score
STRATA Skin Sciences Inc's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SSKN Price Targets Summary
STRATA Skin Sciences Inc
According to Wall Street analysts, the average 1-year price target for
SSKN
is 3.11 USD
with a low forecast of 2.02 USD and a high forecast of 4.31 USD.
Ownership
SSKN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SSKN Price
STRATA Skin Sciences Inc
| Average Annual Return | -24.85% |
| Standard Deviation of Annual Returns | 18.68% |
| Max Drawdown | -90% |
| Market Capitalization | 18.9m USD |
| Shares Outstanding | 34 984 278 |
| Percentage of Shares Shorted | 1.15% |
Company Profile
STRATA Skin Sciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. The company is headquartered in Horsham, Pennsylvania and currently employs 115 full-time employees. The company went IPO on 2005-10-28. The firm is engaged in plastic surgery, developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. The firm's XTRAC excimer laser delivers a targeted therapeutic beam of ultraviolet B (UVB) light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma. Pharos is its excimer laser device that emits concentrated ultraviolet (UV) light and is used as a tool in the treatment of dermatological skin disorders. VTRAC is a UV light lamp system utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
Contact
IPO
Employees
Officers
The intrinsic value of one
SSKN
stock under the Base Case scenario is
1.13
USD.
Compared to the current market price of 0.54 USD,
STRATA Skin Sciences Inc
is
Undervalued by 52%.
You don't have any saved screeners yet
